Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

DermTech Inc (DMTK) USD0.0001

Sell:$34.80 Buy:$34.99 Change: $0.42 (1.22%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.42 (1.22%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.42 (1.22%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

DermTech, Inc. is a molecular dermatology company that focuses on skin cancer. The Company develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The Company provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. It provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. It offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The Company is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. It also offers ResponseTNF product and CytokineEx 17 product.

Contact details

11099 N Torrey Pines Rd Ste 100
United States
+1 (858) 4504222

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.02 billion
Shares in issue:
59.22 million
United States
US dollar

Key personnel

  • John Dobak
    Chief Executive Officer, Director
  • Kevin Sun
    Chief Financial Officer, Treasurer, Secretary
  • Claudia Ibarra
    Chief Operating Officer
  • Ray Akhavan
    Chief Compliance Officer, General Counsel
  • Loren Clarke
    Chief Medical Officer
  • Todd Wood
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.